Lamivudine/zidovudine as a combined formulation tablet: Bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption

Journal of Clinical Pharmacology

Volumn 39, Issue 6, 1999, Pages 593-605

  Moore, K H P ^a   Shaw, S ^a   Laurent, A L ^a   Lloyd, P ^a   Duncan, B ^a   Morris, D M ^a   O'Mara, M J ^a   Pakes, G E ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MIXTURE; DRUG TOLERABILITY; FEEDING; FEMALE; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION;

EID: 0033339123     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922008209     Document Type: Article

References (52)

1. Lamivudine: A review of its antiviral activity, pharrnacokinetic properties and therapeutic efficacy in the management of HIV infection
2. 3'-azido-3'-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro
3. Inhibition of human immunodeficiency virus (HIV-1/HTLV-III(Ba-1)) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'- dideoxynucleosides
4. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase
5. Cellular metabolism of (-) enantiomeric 2'-deoxy-3'-thiacytidine
6. Rapid in vitro selection of human immunodeficiency virus type 1 resistance to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
7. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients
8. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
9. High-level resistance to (-) enantiiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase
10. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1
11. Increased fidelity of drug-selected M184V mutated HIV-1 reverse transcriptase as the basis for the effectiveness of 3TC in HIV clinical trials
12. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter
13. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients: A randomized controlled comparison with zidovudine monotherapy
14. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection
15. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients: A randomized controlled comparison with zidovudine monotherapy
16. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial
17. Antiviral and immunological effects of escalating low doses of zidovudine in HIV-positive patients
18. The effects of twice and four times daily zidovudine on p24 antigenemia in CDC stage II/III patients
19. A comparative trial of zidovudine administered every four versus every twelve hours for the treatment of advanced HIV disease
20. Pharmacokinetics and bioavailability of zidovudine in humans
21. Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal
22. Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS
23. The effect of protein meal on zidovudine pharmacokinetics in HIV-1-infected patients
24. Prolonged, but not diminished, zidovudine absorption induced by a high-fat breakfast
25. Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal
26. Pharmacokinetics of 3TC (GR109714X) administered with and without food to HIV-infected patients
27. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction
28. Pharmacokinetics (PK) of oral lamivudine administered alone and with oral zidovudine (ZDV) in asymptomatic patients with human immunodeficiency virus (HIV) infection
29. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole
30. A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection
31. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: A phase I study
32. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine
33. High-performance liquid chromatographic assay for 2'-deoxy-3'thiacytidine in human serum
34. Differential assay of zidovudine and its glucuronide metabolite in serum and urine with a radioimmunoassay kit
35. Comparative pharmacokinetics of zidovudine (AZT) and its metabolite (G.AZT) in healthy subjects and HIV seropositive patients
36. Comparative pharmacokinetics of zidovudine in healthy volunteers and in patients with AIDS with and without hepatic disease
37. Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis
38. The pharmacokinetics of lamivudine in patients with impaired hepatic function
39. Analysis of potential gender differences in lamivudine (3TC) disposition using population pharmacokinetics from two phase III clinical trials in HIV-infected patients
40. The safety and pharmacokinetics of GW1592U89, zidovudine (ZDV) and lamivudine (3TC) alone and in combination after single-dose administration in HIV-infected patients
41. Pharmacokinetics and antiretroviral activity of lamivudine alone or when co-administered with zidovudine in HIV-infected pregnant women and their offspring
42. Renal disposition and drug interaction screening of (-)-2'-deoxy-3'-thiacytidine (3TC) in the isolated perfused rat kidney
43. The maternal-fetal transfer of lamivudine in the ex vivo human placenta
44. Clinical pharmacokinetics of zidovudine: An update
45. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus
46. Zidovudine adherence in persons with AIDS: The relation of patient beliefs about medication to self-termination of therapy
47. Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the International AIDS Society - USA Panel